Government
Every published round National Health & Medical Research Council took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies National Health & Medical Research Council has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for National Health & Medical Research Council, as distinct from the investments it has made.
Companies National Health & Medical Research Council has backed that another company then bought. An exit for the holding, not a deal National Health & Medical Research Council did.
Stories naming National Health & Medical Research Council. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup of brief items: Memphasys hails fertility device trial results; a concrete recycler is fined; Wurrba, Hazer and University of Queensland land government grants; Aus J gains a North American distribution partner.
Curtin Accelerate has started its 2025 program with twelve Perth founders, offering mentoring, Venture Studio expertise, a modest equity-free grant, AWS credits and potential Kickstart+ investment consideration.
ANDHealth supports the Australian government's new national health research strategy and funding commitments, highlighting the role of its accelerator in driving digital health innovation.
Profile of Sydney genomics startup 23Strands, covering its university and research collaborations, a $1 million grant, an NHMRC-backed project, and its 2020 UNSW Health10X accelerator background.
Techboard's monthly roundup logs June 2022 Australian funding events, including GO1's Series E, Edrolo's Series B, two acquisitions, several new funds reaching closes, and accelerator intake announcements.
Also Techboard
Biotech firm Aravax has added Thomas Ulmer, previously CFO at Immatics and Allergopharma with Merck roles, to its board as its peanut allergy treatment advances after positive phase 1 safety results.
Medical device startup Navi Medical Technologies has received a government research grant to advance commercialisation of its Neonav catheter-placement tool for newborns, developed with Melbourne universities and hospitals.
Relays an Australian Financial Review report that lung imaging company 4DMedical will list on the ASX at a $193 million market capitalisation, profiling founder Andreas Fouras and the technology's development.
The George Institute's commercial arm and its drug development company have secured $53 million from three Australian investors to speed commercialisation of medical research, with Brandon Capital's Ingmar Wahlqvist involved.
South Australian-led scientists will spend four years combining wearable, survey and health data into a tool recommending optimal daily activity mixes, funded by a newly awarded National Health and Medical Research Council grant.
Melbourne biotech Hatchtech received two $10,000 Australian commercialisation prizes and had recently drawn down extra funding to sit alongside its $2.4 million government grant for its head lice treatment.